Read more

August 30, 2019
1 min read
Save

CMHC to offer perspectives on fighting cardiometabolic disease

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Deepak L. Bhatt

Combined, diabetes, obesity and insulin resistance are the most common cause of preventable death in the United States, responsible for millions of deaths and more than $600 billion in health care costs. The Cardiometabolic Health Congress, the largest U.S.-based multidisciplinary conference centered on the management and prevention of CV and metabolic disease, is being held October 10 to 13 in Chicago for health care practitioners committed to joining the fight against cardiometabolic disease.

The event will include a keynote address from Daniel J. Drucker, MD, professor of medicine at the Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital, Toronto, an elected Fellow of the Royal Society for his pioneer research on gut hormones and diabetes treatment, on CV mechanisms and safety of established and emerging peptide therapies.

In addition, Christos S. Mantzoros, MD, DSc, professor of medicine at Harvard Medical School, chief of endocrinology, diabetes and metabolism at the Boston VA Healthcare System and director of human nutrition at Beth Israel Deaconess Medical Center, who is known internationally as a leading pioneer and worldwide expert in obesity and metabolism, will give a talk on nonalcoholic steatohepatitis and nonalcoholic fatty liver disease.

The meeting will also feature an update on FDA news and the past year’s most important late-breaking clinical trials in cardiometabolic medicine, and a presentation by Cardiology Today Editorial Board Member Deepak L. Bhatt, MD, MPH, executive director of interventional cardiovascular programs at Brigham and Women’s Hospital, professor of medicine at Harvard Medical School and investigator for the REDUCE-IT trial, on the treatment of high-risk patients with CVD and elevated triglycerides.

Disclosure: Healio, Cardiology Today and Endocrine Today are official media partners of the Cardiometabolic Health Congress.